Skip to content

Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes

Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02819570
Enrollment
400
Registered
2016-06-30
Start date
2015-11-30
Completion date
2017-12-31
Last updated
2016-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Rupture of Membrane

Keywords

early-onset neonatal sepsis, Prophylactic antibiotics, Pregnancy, PPROM, EOS

Brief summary

The objective of the study is to compare a new antibiotic protocol with the current prophylactic treatment in routine use and to evaluate obstetric and neonatal outcome: preterm labor, chorioamnionitis and early onset sepsis

Detailed description

Preterm premature rupture of membranes (PPROM) occurs in approximately 3% of all pregnancies and is associated with approximately one-third of preterm births. The incidence of chorioamnionitis in women with premature rupture of membranes (PROM) at \< 27, 28 to 36, and \> 37weeks' gestation is 41, 15, and 2%, respectively. Intra-amniotic infection is usually polymicrobial, comprised vaginal or enteric flora including aerobic and anaerobic bacteria and atypical agents, such as Mycoplasma. Group B streptococcus (GBS) has been a frequent pathogen. The American College of Obstetricians and Gynecologists approach to PPROM consists of recommending induction of labor in all women \> 34 weeks' gestation. In the absence of intrauterine infection, placental abruption or non-reassuring fetal heart rate, management of women with PPROM \< 34 weeks consists of hospitalization from the time of diagnosis until delivery, administration of antenatal corticosteroids, and a 7-day course of antibiotic prophylactic therapy to prolong the latency period. Antibiotic therapy has been associated with significant reductions in chorioamnionitis, deliveries within 48 hours, and early-onset (within 3 days of delivery) neonatal sepsis (EOS). The antibiotic regimen in PPROM usually consists of ampicillin intravenously for 48 hours, followed by oral amoxicillin for 5 days (specifically targeting GBS), and a macrolide targeting atypical agents. An increase in EOS due to gram negative Enterobacteriaceae have been reported lately with a relative decrease in GBS related EOS . These data may have an impact on the antibiotic regimen used for PPROM. The Local pathogens distribution in cases of EOS and their antibiotic sensitivity profiles in Northern Israel have been explored in a multicenter study There were 27 neonates diagnosed with EOS with positive blood cultures. Aerobic Enterobacteriaceae accounted for 14 cases (52%) and group B streptococcus for 7 cases (26%). Of the Escherichia coli and Klebsiella sp.,only 38% were sensitive to ampicillin. As a result the most effective antibiotic protocol to cover those pathogens is required. The purpose of the current study is to compare a new antibiotic protocol with the current prophylactic treatment in use and to evaluate pregnancy and neonatal outcome. The diagnosis of preterm premature rupture of membranes (PPROM) is clinical, and is based on visualization of amniotic fluid in the vagina of a woman who presents with a history of leaking fluid. Laboratory tests as Amniosure can be used to confirm the clinical diagnosis when it is uncertain. Women who meet the study criteria and have signed inform consent will be randomly divided in two groups to receive prophylactic antibiotic treatment as follow: 1. I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for additional 5 days+ P.O roxithromycin 150 mg\*2/d for 7 days 2. I.V cefuroxime 750 mg\*3/d for 2days followed by P.O cefuroxime 500 mgx2/d + P.O roxithromycin 150 mg\*2/d for 7 days A course of corticosteroids will be given to all women participating in the study Expectant management: 1. Vital signs \*3/day 2. Uterine tenderness evaluation 3. Complete Blood Count + C-reactive protein every second day 4. Urine culture and GBS recto-vaginal swab 5. Fetal heart monitoring\*6 /d 6. Sonography evaluation every 2-3 days 7. Vaginal swab once a week 8. Fetal movements follow up Labor induction will be conducted at 34 weeks of gestation If chorioamnionitis is suspected amniocentesis should be considered or expeditious delivery

Interventions

DRUGI.V cefuroxime 750 mg*3/d for 2 days
DRUGI.V ampicillin 2 gram x4/d for 2 days
DRUGP.O cefuroxime 500 mgx2/d for 5 days
DRUGP.O roxithromycin 150 mg*2/d for 7 days
DRUGP.O moxypen 500 mgx3/d for 5 days

Sponsors

Western Galilee Hospital-Nahariya
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women with PPROM between 24+0 and 34+0 weeks of gestation who are suitable for conservative management

Exclusion criteria

* P-PROM\>34 weeks of gestation * Suspected fetal distress or chorioamnionitis * Active labor * Drug allergy to one of the study regiments * Immune deficiency * Multiple pregnancy

Design outcomes

Primary

MeasureTime frameDescription
latency periodfrom date of randomization until the date of delivery assessed up to 10 weekstime in days
EARLY NEONATAL SEPSIS - positive blood culturewithin 3 days of deliveryNumber of Participants with early neonatal sepsis
Chorioamnionitis ratefrom day of randomization until date of clinical/laboratory chorioamnionitis diagnosis assessed up to 10 weeksrate of positive cultures

Secondary

MeasureTime frameDescription
Apgar score1 minute 5 minutescore from 0 to 10
Neonatal weightat deliverygrams

Other

MeasureTime frameDescription
Number of participants with adverse events as assessed by umbilical cord acid-based analysis<7at deliverycord ph analysis at delivery (units of moles per liter)
Neonatal intensive care unit (NICU) admission durationdays since delivery until rerelease from NICU, assessed up to 6 monthdays from admission until rerelease from NICU assessed up to 6 month

Countries

Israel

Contacts

Primary ContactMaya Wolf, MD
homesickid@yahoo.com972-507887800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026